In vitro devices and methods for removing secondary membranes

By using the switching operation of dialysate pump and ultrafiltration pump in the extracorporeal blood therapy device, dialysate is intermittently introduced into the blood chamber to remove the secondary membrane on the semipermeable membrane, which solves the problem of secondary membrane formation in existing devices, realizes efficient and simple membrane removal, and improves treatment efficiency.

CN117279678BActive Publication Date: 2026-11-17FRESENIUS MEDICAL CARE HOLDINGS INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202280028440.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-05-14
Filing Date
2022-03-28
Publication Date
2026-11-17
Estimated Expiration
2042-03-28

AI Technical Summary

Technical Problem

Existing extracorporeal blood therapy devices require complex and expensive correction methods when forming secondary membranes during treatment, and existing devices and methods are time-consuming, affecting treatment efficiency.

Method used

An extracorporeal blood therapy device is provided, which intermittently introduces dialysate from the dialysate chamber into the blood chamber through a semipermeable membrane by switching between a dialysate pump and an ultrafiltration pump, detects and removes secondary membrane buildup on the semipermeable membrane, and uses a processor to control the switching of pumps and valves to achieve an automated removal process.

Benefits of technology

It efficiently removes secondary membranes, reduces treatment interruption time, improves treatment efficiency, simplifies device modification processes, and reduces costs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117279678B_ABST
    Figure CN117279678B_ABST
Patent Text Reader

Abstract

An extracorporeal blood therapy device and method are provided for removing a secondary membrane formed on a semipermeable membrane of a dialyzer during extracorporeal blood therapy. The extracorporeal blood therapy device operates in a first operating mode in which a dialysate outlet valve is open, allowing dialysate to flow through the dialyzer supply line, through the dialysate chamber, and into and through the dialyzer discharge line. The extracorporeal blood therapy device operates in a second operating mode to remove the secondary membrane from the semipermeable membrane. During the second operating mode, the dialysate outlet valve remains closed for a period of time to prevent dialysate from flowing through the dialyzer discharge line. A backwashing procedure is performed, wherein a volume of dialysate is introduced from the dialysate chamber through the semipermeable membrane into the blood chamber.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 188,624, filed May 14, 2021, the entire contents of which are incorporated herein by reference. Technical Field

[0003] This invention relates to apparatus and methods for treating blood in vitro, such as through hemodialysis, hemofiltration, and hemodiafiltration. Background Technology

[0004] Kidney replacement therapy systems are used for patients whose blood must be treated outside of their bodies. Extracorporeal blood therapy can be used to remove unwanted substances or molecules from a patient's blood and, if necessary, add desired substances or molecules to the blood. Extracorporeal blood therapy is accomplished by passing blood through a dialyzer. A semipermeable membrane separates the dialyzer into a blood chamber and a dialysate chamber. Blood drawn from the patient is introduced into the blood chamber and flows through the semipermeable membrane. The semipermeable membrane selectively allows substances in the blood to pass from the blood chamber into the dialysate chamber. Depending on the type of treatment, the semipermeable membrane may also selectively allow substances in the dialysate chamber to pass through the semipermeable membrane into the blood chamber.

[0005] Many different types of extracorporeal blood therapy can be performed. In hemofiltration (HF) therapy, blood flows through a semipermeable membrane, and unwanted substances and toxins from the blood are drawn across the membrane and carried away by dialysate. Simultaneously, desired substances are typically added to the blood before or after it passes through the dialyzer, and before it is returned to the patient, usually by dispensing dialysate, or a replacement fluid, into the blood. In hemodialysis (HD) therapy, dialysate containing desired substances is introduced into the dialysate chamber of the dialyzer. Undesirable substances from the blood cross the semipermeable membrane into the dialysate, while desired substances from the dialysate can cross the semipermeable membrane into the blood. In hemodiafiltration (HDF) therapy, blood and dialysate exchange substances, as in HD; additionally, substances are added to the blood, typically by dispensing dialysate into the treated blood before the treated blood is returned to the patient, as in HF. Ultrafiltration (UF) involves removing unwanted substances from the blood through convection that passes through a semipermeable membrane into the dialysate chamber.

[0006] Blood clotting, also known as coagulation, is typically reduced by using anticoagulants such as heparin. However, during treatment, substances from the blood, such as clotted blood, pathogenic cytokines, chemokines, myocardial depressant factors, C'-activating proteins, and the like, can clog the dialyzer's semipermeable membrane. This phenomenon can be called membrane fouling or secondary membrane formation. The effects on the semipermeable membrane are a gradual decrease in flux and an alteration in its selectivity. Membrane fouling is primarily caused by concentration polarization and protein adsorption or deposition on the surface of the semipermeable membrane or in its pores. Concentration polarization results from a concentration gradient caused by the accumulation of solutes near the surface of the semipermeable membrane. This solute accumulation is also known as secondary membrane formation. Protein adsorption or deposition on the surface or in its pores is caused by proteins adsorbed or trapped in the pores of the semipermeable membrane, thus altering the properties of the semipermeable membrane. When some areas of the semipermeable membrane begin to become less effective, measures must be taken to maintain the same therapeutic efficiency.

[0007] The secondary membrane had previously been managed by flushing the blood circuit and replacing the filter. However, these procedures were time-consuming, and treatment had to be stopped. Other devices and methods for removing the secondary membrane during treatment require additional dialysate lines, sensors, pumps, and the like, which are unnecessarily complex and require costly modifications to the extracorporeal blood therapy device.

[0008] Therefore, there is a need for an apparatus and method for removing secondary membranes formed during extracorporeal blood therapy, which is efficient and allows for inexpensive modifications to existing extracorporeal blood therapy devices. Summary of the Invention

[0009] One feature of the present invention is to provide an in vitro apparatus and method for removing a secondary membrane from the semipermeable membrane of a dialyzer.

[0010] Another feature of the present invention is to provide an extracorporeal device and method for removing a secondary membrane from a semipermeable membrane of a dialyzer during extracorporeal treatment of a patient.

[0011] Another feature of the present invention is to provide an extracorporeal device for intermittently removing a secondary membrane from the semipermeable membrane of a dialyzer during extracorporeal treatment of a patient.

[0012] Another feature of the invention is to provide an improvement to the extracorporeal device for intermittently removing a secondary membrane from the semipermeable membrane of a dialyzer during extracorporeal treatment of a patient.

[0013] Another feature of the present invention is to provide an extracorporeal device that intermittently introduces a controlled volume of dialysate from the dialysate chamber through a semipermeable membrane into the blood chamber of a dialyzer to remove a secondary membrane from the semipermeable membrane during extracorporeal treatment of a patient.

[0014] Another feature of the present invention is to provide an in vitro device that detects the accumulation of a secondary membrane on the semipermeable membrane of a dialyzer, and removes the secondary membrane from the semipermeable membrane when the accumulation is detected during in vitro treatment of a patient.

[0015] Another feature of the present invention is to provide a processor for an extracorporeal device, the processor being programmed or otherwise configured to execute a set of instructions to remove a secondary membrane from a semipermeable membrane during extracorporeal treatment of a patient.

[0016] Another feature of the present invention is to provide a processor for an in vitro device, the processor being programmed or otherwise configured to execute a set of instructions to detect the accumulation of a secondary membrane on a semipermeable membrane of a dialyzer, and, when the accumulation is detected, remove the secondary membrane from the semipermeable membrane during in vitro treatment of a patient.

[0017] Additional features and advantages of the invention will be set forth in part in the description which follows, and in part will be apparent from the description, or may be learned by practice of the invention. The objects and other advantages of the invention will be realized and obtained by means of the elements and combinations particularly pointed out in the specification and appended claims.

[0018] To achieve these and other advantages, and in accordance with the purposes of this invention, as embodied and broadly described herein, the present invention relates to an extracorporeal blood therapy device. The extracorporeal blood therapy device includes a dialyzer having a blood chamber, a dialysate chamber, a dialysate inlet, a dialysate outlet, and a semipermeable membrane. The blood chamber and the dialysate chamber are separated from each other by the semipermeable membrane. A dialyzer supply line leads to the dialysate inlet and is configured to supply dialysate to the dialysate chamber. A dialyzer discharge line extends from the dialysate outlet and is configured to discharge dialysate from the dialysate chamber. A dialysate pump is configured to pump dialysate through the dialyzer supply line into the dialysate chamber and pump it out of the dialysate chamber through the dialyzer discharge line.

[0019] For example, the flow pump and / or ultrafiltrate pump returning downstream of the pipeline can be configured to switch between an operating state and a non-operating state. In the operating state, the ultrafiltrate pump draws fluid from the blood chamber through the semipermeable membrane into the dialysate chamber and then exits the dialysate chamber.

[0020] The dialysate pump is configured to operate in both a first operating mode and a second operating mode of the extracorporeal blood therapy device. The first operating mode operates with the dialysate outlet valve open, allowing dialysate to flow through the dialyzer supply line, through the dialysate chamber, and into and through the dialyzer discharge line. The second operating mode operates with the dialysate outlet valve continuously closed for a period of time, the ultrafiltration pump switching to the non-operating state to prevent dialysate from flowing through the dialyzer discharge line, and allowing a certain volume of dialysate to pass from the dialysate chamber through the semipermeable membrane into the blood chamber. The balancing chamber can be configured such that the valve is closed and then reopened to allow balancing chamber circulation to complete.

[0021] The present invention also relates to an extracorporeal blood therapy device having a processor and a sensor or sensor system in communication with the processor. The sensor or sensor system is configured to generate sensor data, and the processor is configured to process the sensor data. The processor is further configured to switch the extracorporeal blood therapy device from a first operating mode to a second operating mode based on the processed sensor data and maintain this switching for a period of time.

[0022] The present invention also relates to a processor configured to determine, based on the sensor data, that a secondary membrane is accumulating on the semipermeable membrane. When the processor determines that the secondary membrane is accumulating on the semipermeable membrane, the processor accelerates the switching of the extracorporeal blood therapy device from a first operating mode to a second operating mode for a period of time.

[0023] The present invention also relates to a blood therapy method comprising performing blood therapy on a patient using the extracorporeal blood therapy device of the present invention, and intermittently removing a secondary membrane from the semipermeable membrane during the blood therapy.

[0024] The present invention also relates to a processor for an extracorporeal device, the processor being programmed or otherwise configured to execute a set of instructions to remove a secondary membrane from a semipermeable membrane during extracorporeal treatment of a patient.

[0025] The present invention also relates to a processor for an extracorporeal device, the processor being programmed or otherwise configured to execute a set of instructions to detect the accumulation of a secondary membrane on a semipermeable membrane of a dialyzer, and, when the accumulation is detected, remove the secondary membrane from the semipermeable membrane during extracorporeal treatment of a patient.

[0026] Furthermore, the present invention relates to a blood treatment method. The method includes: a) providing an extracorporeal blood treatment device including a dialyzer having a blood chamber, a dialysate chamber, and a semipermeable membrane, the blood chamber and the dialysate chamber being separated from each other by the semipermeable membrane, the dialysate chamber having a dialysate outlet valve; b) treating blood in a first operating mode by pumping dialysate through the dialysate chamber using a dialysate pump, pumping blood through the blood chamber using a blood pump, and drawing ultrafiltrate from the dialysate chamber using an ultrafiltrate pump; c) detecting accumulation of a secondary membrane on the semipermeable membrane while treating blood in the first operating mode; and d) switching from the first operating mode to a second operating mode upon detection of the accumulation, the second operating mode including continuously closing the dialysate outlet valve for a period of time and shutting off the ultrafiltrate pump to prevent dialysate from flowing out of the dialysate chamber, such that a certain volume of dialysate flows through the semipermeable membrane from the dialysate chamber to the blood chamber. Ultrafiltration does not require flow restriction, but it can be controlled to ensure accurate ultrafiltration volume calculation.

[0027] It should be understood that the foregoing general description and the following detailed description are exemplary and explanatory only, and are intended to provide further explanation of the invention as claimed in the claims. Attached Figure Description

[0028] The accompanying drawings illustrate various design features of the invention. Unless otherwise indicated, similar reference numerals in different figures may refer to similar features. The drawings are not necessarily drawn to scale.

[0029] Figure 1 This is a schematic diagram of an extracorporeal blood therapy device according to an embodiment of the present invention.

[0030] Figure 2A It is a table of device setting variables and corresponding correction coefficients used to correct the reference time and the generation time interval.

[0031] Figure 2B It is a table of device setting variables and corresponding correction coefficients used to correct the reference time and the generation time interval.

[0032] Figure 3 It is a table of device output variables and corresponding correction coefficients used to correct the reference time and the generation time interval.

[0033] Figure 4A and Figure 4B These are the left and right portions of a schematic diagram of an extracorporeal blood therapy device according to an embodiment of the present invention.

[0034] Figure 5A and Figure 5BThese are the top and bottom portions of a flowchart illustrating the method steps to be performed according to an embodiment of the present invention. Detailed Implementation

[0035] This invention includes an extracorporeal blood therapy device and a method of treatment using the extracorporeal blood therapy device. The extracorporeal blood therapy device includes a dialyzer having a blood chamber, a dialysate chamber, a dialysate inlet, a dialysate outlet, and a semipermeable membrane. The blood chamber and the dialysate chamber are separated from each other by the semipermeable membrane. A dialyzer supply line leads to the dialysate inlet and is configured to supply dialysate to the dialysate chamber. A dialyzer discharge line extends from the dialysate outlet and is configured to drain dialysate from the dialysate chamber. A dialysate pump is configured to pump dialysate through the dialyzer supply line to the dialysate chamber and pump it out of the dialysate chamber through the dialyzer discharge line. A dialysate outlet valve can be opened and closed to allow and restrict the flow of dialysate from the dialysate chamber of the dialyzer, respectively.

[0036] The extracorporeal blood therapy device may also include a balancing device with a balancing chamber. A balancing supply line leads to the balancing chamber and is configured to supply fresh dialysate from a dialysate source into the balancing chamber. A balancing discharge line extends from the balancing chamber and is configured to drain used dialysate from the balancing chamber into the discharge system. During perfusion, fresh dialysate can circulate through different halves of the balancing chamber and can be discharged. A dialyzer supply line extends from the balancing chamber and is configured to supply dialysate from the balancing chamber to the dialysate chamber, and a dialyzer discharge line leads to the balancing chamber and is configured to supply dialysate from the dialysate chamber to the balancing chamber.

[0037] The extracorporeal blood therapy device is configured to operate in a first operating mode and a second operating mode during patient treatment or during device perfusion. The first operating mode operates with the dialysate outlet valve open, allowing dialysate to flow through the dialyzer supply line, through the dialysate chamber, and into and through the dialyzer discharge line. The second operating mode operates with the dialysate outlet valve continuously closed for a period of time to prevent dialysate flow through the dialyzer discharge line and to allow a volume of dialysate to pass from the dialysate chamber through a semipermeable membrane into the blood chamber. During treatment, dialysate flows back from the dialysate chamber to the blood chamber through the semipermeable membrane, removing secondary membrane buildup, which allows for more efficient flow through the semipermeable membrane and thus more efficient treatment of the patient. During perfusion, dialysate flows back from the dialysate chamber to the blood chamber through the semipermeable membrane, removing secondary membrane buildup present in a reused dialyzer, which also allows for more efficient subsequent treatment of the patient.

[0038] The extracorporeal blood therapy device includes an extracorporeal blood circuit. The extracorporeal blood circuit is in fluid communication with the dialyzer via a blood chamber inlet and a blood chamber outlet. The extracorporeal blood circuit includes a blood pump, a blood supply line leading to the blood chamber inlet, and a blood removal line leading to the blood chamber outlet. The blood pump is configured to pump blood through the blood supply line and the blood chamber inlet into the blood chamber, and pump blood out of the blood chamber through the blood chamber outlet and the blood removal line. During patient treatment, blood flows through the blood chamber of the dialyzer, and dialysate containing desired substances is introduced into the dialysate chamber of the dialyzer. Undesirable substances from the blood cross a semipermeable membrane into the dialysate, while desired substances from the dialysate can cross a semipermeable membrane into the blood.

[0039] In some embodiments, the extracorporeal blood therapy device is capable of ultrafiltration. An ultrafiltration line branches off from the dialyzer discharge line downstream of the dialysate outlet valve. An ultrafiltrate pump is disposed on the ultrafiltration line. The ultrafiltrate pump is configured to switch between an operating state and a non-operating state. During the operating state, the ultrafiltrate pump draws fluid from the blood chamber, through a semipermeable membrane into the dialysate chamber, and out of the dialysate chamber through the dialysate outlet valve. Ultrafiltration further enhances the removal of unwanted substances from the blood through convection flowing through the semipermeable membrane into the dialysate chamber.

[0040] The extracorporeal blood therapy device may also include treatment with a replacement fluid. In such embodiments, the extracorporeal blood therapy device includes a replacement material line and a replacement material pump disposed on the replacement material line. In some embodiments, the replacement material line branches off from the dialyzer supply line and connects to a blood removal line for post-dilution treatment. In other embodiments, the replacement material line branches off from the dialyzer supply line and connects to a blood supply line for pre-dilution treatment. The replacement material line may supply a first replacement material pump and a second replacement material pump disposed on the replacement material line and may be connected to both the blood supply line and the blood removal line for mixing and dilution treatment. The replacement material pump may be configured to pump replacement fluid from the dialyzer supply line to the blood removal line and / or the blood supply line via the replacement material line after passing through a second filter to further remove impurities, such as those resulting from direct contact between the replacement material and blood. Displacement fluid can be introduced during hemofiltration treatment, in which blood flows through a semipermeable membrane and desired substances are added to the blood by distributing displacement fluid into the blood before and / or after the blood passes through the dialyzer, while an equal volume of fluid is removed from the blood chamber of the dialyzer to maintain fluid volume. Displacement fluid can also be introduced during hemodiafiltration treatment, in which blood and dialysate exchange substances as in hemodialysis, and in addition, displacement fluid is added to the blood while an equal volume of fluid is removed from the blood chamber of the dialyzer to maintain fluid volume.

[0041] Each pump and valve in the extracorporeal therapy device can be controlled according to the type of treatment and whether the device is operating in a first or second operating mode. During the first operating mode of hemodialysis treatment: the dialysate valve is open, awaiting an alarm-free state; the dialysate pump is activated to continuously pump dialysate through the dialysate chamber; and the blood pump is activated to continuously pump blood through the blood chamber. During the second operating mode of hemodialysis treatment: the dialysate outlet valve remains closed for a period of time; compared to the first operating mode, the dialysate pump speed can be increased, decreased, or maintained at a certain speed; and compared to the first operating mode, the blood pump can be turned off, or the blood pump speed can be increased, decreased, or maintained at a certain speed.

[0042] During the first operating mode of hemofiltration therapy: the dialysate valve is open; the dialysate pump is closed or operates at a minimum rate, e.g., 100 ml / min; the blood pump is activated to continuously pump blood through the blood chamber; the ultrafiltrate pump is in the operating state in which it draws fluid from the blood chamber through the semipermeable membrane into the dialysate chamber and removes it from the dialysate chamber; and the replacement pump is activated to pump replacement material to the blood supply line or the blood removal line or both. During the second operating mode of hemofiltration therapy: the dialysate outlet valve remains closed for a period of time; the dialysate pump pumps dialysate through the dialysate chamber; the replacement pump is closed; the ultrafiltrate pump is in a non-operating state; and compared to the first operating mode, the blood pump may be closed or the blood pump speed may be increased, decreased, or maintained at a certain speed.

[0043] During the first operating mode of hemodialysis filtration treatment: the dialysate valve is open; the dialysate pump is activated to continuously pump dialysate through the dialysate chamber; the ultrafiltrate pump is in the operating state, in which the ultrafiltrate pump draws fluid from the blood chamber through the semipermeable membrane into the dialysate chamber and removes it from the dialysate chamber; the replacement pump is activated to pump replacement material to the blood supply line or the blood removal line or both; and the blood pump is activated to continuously pump blood through the blood chamber. During the second operating mode of hemodialysis filtration treatment: the dialysate outlet valve remains closed for a period of time; compared to the first operating mode, the dialysate pump speed may be increased, decreased, or maintained at a certain speed; the replacement pump is closed; the ultrafiltrate pump is in a non-operating state; and the blood pump may be closed or, compared to the first operating mode, the blood pump speed may be increased, decreased, or maintained at a certain speed.

[0044] As described above, the second operating mode operates in a configuration where the dialysate outlet valve is continuously closed for a period of time, preventing dialysate from flowing through the dialyzer drain line and allowing a certain volume of dialysate to pass from the dialysate chamber through the semipermeable membrane into the blood chamber. The extracorporeal therapy device can enter the second operating mode multiple times during treatment, each of which has a relatively short duration. Timing can be based on the possibility of dialysate flow rates ranging from 100 ml / min to 1000 ml / min, as is typical on some dialysis machines, such as the Fresenius Medical Care Model 5008s. At a high flow rate of 1000 ml / min, a balancing cycle may take only about 2 seconds, and at a low flow rate of 100 ml / min, a balancing cycle may take about 21 seconds. These times can be increased by approximately 15% to 20% when the dialysate return line valve closes. Without a balancing chamber, only the closing time is relevant. Taking these factors into account, if the machine is not equipped with a balancing chamber, the duration of the second operating mode can be in the range of approximately 0.3-5 seconds; if the machine is equipped with a balancing chamber, the duration of the second operating mode can be in the range of 2-30 seconds. The duration of the second operating mode can depend on the dialysate flow rate to ensure the introduction of a known volume of fluid.

[0045] Due to the short duration of one or more second operating modes, a small amount of dialysate can flow from the dialysate chamber into the blood chamber through a semipermeable membrane. For example, the volume of dialysate entering the blood chamber can be from 3 ml to 6 ml, or up to 20 ml. Larger volumes can be used when operating in perfusion mode or under conditions that induce the formation of higher secondary membranes.

[0046] During each second operating mode, a small amount of dialysate is introduced into the bloodstream. During a subsequent first operating mode in each of the second operating modes, this small amount of dialysate can be removed from the bloodstream. For this purpose, the ultrafiltration pump can be configured to operate at a faster rate during at least one time period in the first operating mode (different from the initial first operating mode) to remove a volume of liquid from the blood chamber equal to the volume of dialysate introduced in the previous second operating mode. For example, the ultrafiltration pump can be configured to remove, for example, a certain volume of liquid from the blood, which can be from 3 ml to 6 ml, or up to 20 ml. Larger volumes can be removed when operating under conditions that induce the formation of higher secondary membranes.

[0047] Extracorporeal therapy devices may use flow pumps, degassing pumps, auxiliary pumps, combinations thereof, and the like. One or more of such pumps can drive fresh dialysate, cleansing solution, or the like to circulate through the dialysate circuit. The pumps can be controlled to circulate liquids, such as perfusion solution, dialysate, cleansing solution, flushing solution, combinations thereof, or the like, through the dialysate circuit.

[0048] The extracorporeal blood therapy device of the present invention may include a computing system. The computing system may include a processor, memory, and a user interface. A data processing program (software) may be loaded onto the memory and run on the processor to execute method steps. The computing system communicates with dialysate pumps, blood pumps, replacement pumps, ultrafiltrate pumps, valves, and sensors via wired or wireless communication. The computing system can automatically control the pumps and valves via software-provided instructions, and the user can manually control the pumps and valves using the user interface. It can run pre-programmed routines, implement artificial intelligence to better control treatment and / or future treatments, and implement similar control features.

[0049] Sensors can be configured to generate sensor data for the extracorporeal blood therapy device, and a computing system can be configured to use the sensor data to determine when to change the extracorporeal blood therapy device from a first operating mode to a second operating mode, or from a second operating mode back to a first operating mode, or both. In some embodiments, the computing system is configured to operate the extracorporeal blood therapy device in an initial first operating mode phase for a primary operating time period, which begins at the start of treatment. The primary operating time period can include 20 to 80 minutes, 30 to 70 minutes, 40 to 60 minutes, or 50 minutes. When the primary operating time period expires, the computing system can automatically switch the extracorporeal blood therapy device from the first operating mode to a second operating mode for a secondary operating time period. If the machine is not equipped with a balancing chamber, the duration of the second operating mode can be in the range of approximately 0.3 to 5 seconds; if the machine is equipped with a balancing chamber, the duration of the second operating mode can be in the range of 2 to 30 seconds. The duration of the second operating mode can depend on the dialysate flow rate to ensure the introduction of a known volume of fluid. The length of each backflushing routine or the second operating mode can be calculated independently.

[0050] The main operating time period can be calculated based on a reference time that is automatically adjusted according to variables set by at least one device, or multiple device variables. The reference time can be preset to, for example, 60 minutes, 70 minutes, 75 minutes, 80 minutes, 90 minutes, or similar.

[0051] Device setting variables may include the type of dialyzer used during treatment, the type of treatment selected (hemofiltration, hemodialysis, or hemodiafiltration), replacement pump rate, ultrafiltrate pump rate, blood pump rate, whether the replacement fluid is supplied to the blood line upstream or downstream of the dialyzer, the preset ultrafiltration coefficient associated with the dialyzer, the amount of hemodiafiltration bolus, or a combination thereof. Device setting variables are used to determine the degree to which the calculation system corrects for the baseline time of the main operating period. For example, if the ultrafiltrate pump rate, blood pump rate, or a combination thereof is set to an increased rate, the baseline time decreases because this change increases the rate of secondary membrane buildup. If the replacement fluid flow rate is increased and post-dilutement is added, the expected result is that more secondary membranes will form.

[0052] As the baseline time decreases, the computational system can switch the extracorporeal blood therapy device from a first operating mode to a second operating mode more quickly to remove excess buildup of the secondary membrane and maintain efficient treatment. For example, early backflushing may be desirable for better urea removal. Furthermore, the type of treatment can affect the rate of secondary membrane buildup. For instance, compared to hemodialysis, if replacement fluid is introduced into the blood after the dialyzer, the secondary membrane can build up at a faster rate during hemofiltration and hemodiafiltration. Alternatively, compared to hemodialysis, if replacement fluid is introduced into the blood before the dialyzer due to blood dilution, secondary membrane formation can build up at a slower rate during hemofiltration and hemodiafiltration. Therefore, compared to hemodialysis, the computational system adjusts the baseline time during hemodiafiltration or hemofiltration, for example, based on device setting data input before, during, or after treatment.

[0053] During the treatment process, the computing system periodically receives sensor data from the sensors. Using the sensor data, the computing system can determine device output variables and adjust the baseline time for the main operating period based on these variables. In some embodiments, sensors sense urea levels and pressures in the dialysate and blood lines of the extracorporeal blood therapy device, and the sensor data is provided to the computing system. The computing system can use the sensor data to determine device output variables such as changes in venous pressure, transmembrane pressure, ultrafiltration coefficient, hematocrit, clearance rate, or combinations thereof. The computing system can then adjust the baseline time for the main operating period based on these device output variables. For example, if an increase in transmembrane pressure is detected, a decrease in the ultrafiltration coefficient is detected, or a combination thereof, the computing system can reduce the baseline time based on the acquired device output variables. This is because an increase in transmembrane pressure and a decrease in the ultrafiltration coefficient indicate higher accumulation on the secondary membrane, thus requiring a faster initiation of the second operating mode.

[0054] In some embodiments, the duration for which the dialysate outlet valve is closed during the secondary operating period of the second operating mode may include the baseline volume to be delivered from the dialysate chamber to the blood chamber of the dialyzer. The duration of the dialysate outlet valve closure will primarily depend on the dialysate flow rate to ensure the baseline volume is delivered from the dialysate chamber to the blood chamber of the dialyzer. Furthermore, the baseline volume to be delivered from the dialysate chamber to the blood chamber of the dialyzer itself may be automatically corrected by a calculation system based on device setting variables and device output variables. Similar to corrections for the primary operating period, examples of device setting variables may include the type of dialyzer used during treatment, the type of treatment selected (hemofiltration, hemodialysis, or hemodiafiltration), the blood pump rate, the replacement pump rate, the ultrafiltrate pump rate, or combinations thereof. If the replacement pump rate, the ultrafiltrate pump rate, the blood pump rate, or combinations thereof increases, the baseline volume delivered to the blood chamber of the dialyzer during the secondary operating period may increase because such a device setting can increase the rate of accumulation of the secondary membrane. Therefore, the baseline volume of blood to be delivered to the dialyzer chamber during the secondary operation period can be increased, allowing the computational system to maintain the extracorporeal blood therapy device in the second operating mode for a longer period to remove excess buildup in the secondary membrane, thereby maintaining efficient treatment. Examples of device output variables may include changes in venous pressure, transmembrane pressure, ultrafiltration coefficient, hematocrit, clearance rate, or combinations thereof, determined by the computational system using sensor data from sensors. The computational system can then adjust the baseline volume of blood to be delivered to the dialyzer chamber during the secondary operation period based on the device output variables. For example, if an increase in transmembrane pressure is detected, a decrease in ultrafiltration coefficient is detected, or a combination thereof, the computational system can increase the baseline volume of blood to be delivered to the dialyzer chamber during the secondary operating mode based on the acquired device output variables. This is because an increase in transmembrane pressure and a decrease in ultrafiltration coefficient indicate higher buildup in the secondary membrane, thus requiring the second operating mode to deliver a larger volume of fluid from the dialysate chamber to the dialyzer's blood chamber.

[0055] In some embodiments, the computing system is configured to switch the extracorporeal blood therapy device between a first operating mode and a second operating mode in an alternating sequence at a predetermined frequency during treatment. Each of the plurality of operating modes includes its own operating time period. The computing system is configured to adjust the frequency by modifying each of the respective operating time periods based on device setting variables or device output variables, or both. For example, if the ultrafiltration pump rate, blood pump rate, or a combination thereof is set to an increased rate, the baseline time is reduced because this change increases the rate of secondary membrane buildup. If the displacement fluid flow rate is increased and post-dilution is added, the expected result is that more secondary membrane formation will occur. Furthermore, if an increase in a device output variable including transmembrane pressure is detected, a decrease in the ultrafiltration coefficient is detected, or a combination thereof, the computing system can increase the frequency of the second operating time period because the increase in transmembrane pressure and the decrease in the ultrafiltration coefficient indicate higher secondary membrane buildup, thus requiring operation of the second operating mode at a higher frequency.

[0056] By comparing the ultrafiltration coefficient, transmembrane pressure, or a combination thereof with initial calculated values, the calculation system can adjust the frequency between the first and second operating modes of the extracorporeal blood therapy device. For example, the calculation system can determine the ultrafiltration coefficient or transmembrane pressure, or both, at the start of treatment or within 1 to 20 minutes, 5 to 15 minutes, or 10 minutes after treatment start to determine the initial calculated values. If the ultrafiltration coefficient or transmembrane pressure, or both, is determined after a significant delay from the start of treatment, the initial calculated values ​​of the ultrafiltration coefficient and transmembrane pressure can be adjusted accordingly. For example, the ultrafiltration coefficient typically decreases by 33% during the first 30 minutes of treatment. For initial calculated values ​​calculated after 10 minutes, the initial calculated values ​​can be adjusted using the following equation: For t less than 30, the adjusted initial calculated value of the ultrafiltration coefficient = (initial calculated value of ultrafiltration coefficient @ time t) * (1 + (.33 * (time t) / 30)). If the initial calculated value of the ultrafiltration coefficient occurs after 30 minutes, 1.33 is used as the multiplier.

[0057] After the computing system switches the extracorporeal blood therapy device from a first operating mode to a second operating mode and then back to the first operating mode, the computing system can use sensors to re-determine the ultrafiltration coefficient or transmembrane pressure, or both, and can then compare these values ​​with the initial calculated values ​​to determine the extent of secondary membrane removal. If it is determined that secondary membrane buildup has not been properly removed, the computing system can adjust the frequency and duration of the first and second operating modes of the extracorporeal blood therapy device. Each time the second operating mode is switched back to the first operating mode, the computing system can determine the ultrafiltration coefficient or transmembrane pressure, or both, to determine if any adjustments to the frequency and duration are necessary.

[0058] The number of backwashes and the timing of each backwash can be determined independently and based on initial settings, device output data, rate of change, combinations thereof, or similar factors. If the machine is not equipped with a balancing chamber, the duration of the second operating mode or backwash can be in the range of approximately 0.3–5 seconds; if the machine is equipped with a balancing chamber, the duration of the second operating mode or backwash can be in the range of 2–30 seconds. The duration of the second operating mode can depend on the dialysate flow rate to ensure the introduction of a known volume of fluid. Control signals received from the computing system can control valves, pumps, or combinations thereof to initiate backwashing, maintain backwashing time, terminate backwashing, and / or switch back to the first operating mode.

[0059] This invention also enables existing extracorporeal blood therapy devices to be programmed with computer programs, instruction sets, algorithms, combinations thereof, or the like, as described herein. New or existing devices and processors, such as those including or controlling existing valves, pumps, and sensors, can be configured or programmed, or both, to perform the methods and treatments according to the invention.

[0060] Figure 1 This is a schematic diagram showing the various components of an extracorporeal blood therapy device that can implement the teachings herein. The extracorporeal blood therapy device includes a blood circuit and a dialysate circuit. The blood circuit and dialysate circuit, together with dialyzer 1, form the fluid system of the extracorporeal blood therapy device. Dialyzer 1 has a blood chamber 2 and a dialysate chamber 3 separated by a semipermeable membrane 4. A blood supply line 5, along which a blood pump 6 is disposed, extends from an arterial patient port 7 to a blood inlet 48 of the blood chamber 2. An arterial valve 8 may be located upstream of the blood pump 6 along the blood supply line 5. A blood removal line 9, in which a liquid chamber 10 may be disposed, extends from the blood outlet 52 of the blood chamber 2 to a venous patient port 11. A venous valve 12 may be located downstream of the liquid chamber 10 along the blood removal line 9.

[0061] The dialysate circuit has a dialysate source 13 for providing fresh dialysate. The dialysate source 13 is connected via a first portion 14A of a dialysate supply line 14 to the inlet of the first chamber 15A of the balance chamber pair 15. A second portion 14B of the dialysate supply line 14 connects the outlet of the first chamber 15A to the dialysate inlet 40 of the dialysate chamber 3. The fresh dialysate can be used as a flushing liquid or a preparation liquid. The dialysate outlet 44 of the dialysate chamber 3 is connected via a first portion 16A of a dialysate removal line 16 to the inlet of the second chamber 15B of the balance chamber 15. A dialysate flow pump 17 is disposed along the first portion 16A of the dialysate removal line 16. The outlet of the second chamber 15B is connected via a second portion 16B of the dialysate removal line 16 to a discharge system 18. The balance chamber 15 may have more than two chambers.

[0062] The dialysate inlet valve 19 is located upstream of the dialysate supply line 14 in the dialysate chamber 3. The dialysate outlet valve 20 is located downstream of the dialysate removal line 16 in the dialysate chamber 3. An air separation chamber or air separator 55 may be located downstream of the dialysate outlet valve 20 and upstream of the dialysate pump 17 along the first section 16A of the dialysate removal line 16. The water level in the air separator 55 is as follows: Figure 1 As shown. The dialysate inlet valve 19 and dialysate outlet valve 20 can be electromagnetically actuated valves.

[0063] Ultrafiltrate line 23 branches from air separator 55 to a second section 16B of dialysate removal line 16. An ultrafiltrate pump 24 is provided along ultrafiltrate line 23. An air removal line 25 extends from the top of air separator 55 to the second section 16B of dialysate removal line 16, and a bypass valve 26 is provided along the air removal line 25. Blood pump 6, dialysate pump 17, and ultrafiltrate pump 24 can be occluded pumps. If the pumps are occluded pumps, some valves used to create a closed volume can be omitted.

[0064] The extracorporeal blood therapy device may also include a displacement pump 35 for pumping displacement fluid, also referred to herein as displacement fluid, to an extracorporeal blood circuit upstream or downstream of the blood chamber 2 via a displacement line 36. For example, a displacement valve 37 may be located upstream of the displacement pump 35 along the displacement line 36, such as... Figure 1 As shown. Whether the replacement fluid is injected into the extracorporeal blood circuit upstream or downstream of the blood chamber, it can affect the accumulation of secondary membranes. As described herein, the difference in accumulation caused by two different injection points can be accounted for by applying appropriate correction factors. Whether the replacement fluid is injected continuously or as a bolus into the extracorporeal blood circuit, and whether it is injected upstream or downstream of the blood chamber, it can also affect the accumulation of secondary membranes. As described herein, the difference in accumulation caused by two different bolus injection points can be accounted for by applying appropriate correction factors.

[0065] The extracorporeal blood therapy device may include a computing system 27 for controlling pumps and valves. The computing system 27 may include, for example, a general-purpose processor 27A, a digital signal processor (DSP) for continuously processing digital signals, a microprocessor, an application-specific integrated circuit (ASIC), an integrated circuit composed of logic elements, a field-programmable array (FPGA), or other integrated circuits (ICs) or hardware components for performing the various method steps described herein. The computing system 27 also includes a memory 27B storing data processing programs (software) that can run on hardware components to perform the method steps. The computing system 27 also includes a user interface 27C. The user interface 27C may include hardware, software, firmware, or a combination thereof to enable a user to communicate with and send commands to the computing system 27. For example, the user interface 27C may include, but is not limited to, a display, a touchscreen display, a keyboard, a keypad, a mouse, a virtual reality interface, an augmented reality interface, a voice command interface, one or more speakers, one or more microphones, combinations thereof, and the like.

[0066] The computing system 27 is connected via control lines or data lines (not shown) to the dialysis pump 17, blood pump 6, ultrafiltrate pump 17, displacement pump 35, dialysate inlet valve 19, dialysate outlet valve 20, blood inlet valve 8, blood outlet valve 12, bypass valve 26, and displacement valve 37, so that the flow rates of these pumps can be set and the valves and bypass valves can be actuated via the computing system 27. The valves and bypass valves have actuating components (not shown) that can act on the fluid lines.

[0067] The extracorporeal blood therapy device may also include sensors 32, 33, 41, and 47 connected to the computing system 27 via data lines 32A, 33A, 41A, and 47A, respectively. Sensor 47 is a dialysate supply pressure sensor that measures the pressure within the dialysate supply line 14. Sensor 32 is a dialysate removal pressure sensor that measures the pressure within the dialysate first section 16A of the dialysate removal line. Sensor 41 is a blood supply pressure sensor that measures the blood pressure within the blood supply line 5 downstream of the blood pump 6. Sensor 33 is a blood removal pressure sensor that measures the pressure within the blood removal line 9. Sensors 32, 33, 41, and 47 measure the pressure within their respective fluid lines and generate sensor data, which is sent to and processed by the computing system 27. The computing system 27 can use the sensor data to determine transmembrane pressure, ultrafiltration coefficient, and other values. Sensors may also include urea sensors, air separator pressure sensors, and similar sensors that can be used in the extracorporeal blood therapy device. Sensors 41 and 47 may optionally be included, for example, to improve the accuracy of the transmembrane pressure and the calculated ultrafiltration coefficient during treatment.

[0068] Sensors 32, 33, 41 and 47 are configured to generate sensor data for the extracorporeal blood therapy device, and computing system 27 is configured to use the sensor data to determine when to change the extracorporeal blood therapy device from a first operating mode to a second operating mode and from the second operating mode back to the first operating mode.

[0069] In use, the user can begin treatment by inputting device setting variables into the calculation system 27, or by preloading device setting variables into the calculation system 27. Device setting variables may include, but are not limited to, the type of dialyzer used during treatment, the type of treatment selected (e.g., hemofiltration, hemodialysis, or hemodiafiltration), the displacement fluid pump rate, the ultrafiltrate pump rate, the blood pump rate, whether the replacement material is supplied to blood lines upstream or downstream of the dialyzer, the preset ultrafiltration coefficient, the amount of hemodiafiltration bolus, whether the bolus is in pre-dilution or post-dilution, and combinations thereof. The calculation system 27 can adjust the reference time for the primary operating time period, the reference time for the secondary operating time period, or a combination thereof based on the device setting variables. To begin treatment, the arterial patient port 7 and the venous patient port 11 are connected to the patient, and the extracorporeal blood therapy device begins treatment in the first operating mode for the continuously adjusted primary operating time period. Once the adjusted primary operating time period has expired, the calculation system 27 can switch the extracorporeal blood therapy device to the second operating mode for the continuously adjusted second operating time period.

[0070] When the extracorporeal blood therapy device is operating, the computing system 27 periodically receives sensor data from sensors 32, 33, 41, and 47. Using the sensor data, the computing system 27 can determine device output variables and adjust the reference times for primary and secondary operating periods based on these device output variables. In some embodiments, sensors 32, 33, 41, and 47 sense clearance and pressure levels in dialysate lines 14 and 16 and blood lines 5 and 9 of the extracorporeal blood therapy device, and the sensor data can be sent to the computing system 27. The computing system 27 then uses the sensor data, based on changes in venous pressure, transmembrane pressure, ultrafiltration coefficient, hematocrit, changes in transmembrane pressure, changes in clearance, combinations thereof, and the like, to determine device output variables and select predetermined coefficients or corrections. For example, along blood line 5, where a fluid management monitoring tool can be attached, photo-optical technology is incorporated to non-invasively measure absolute hematocrit and continuous oxygen saturation. Furthermore, this attachment device, commonly referred to as a CLiC, can also be configured to calculate the percentage changes in intravascular blood volume and oxygen saturation in dialysis patients. Then, the computing system 27 can adjust the reference time for the primary and secondary operation periods based on the device output variables.

[0071] As an example, if an increase in transmembrane pressure is detected, or a decrease in the ultrafiltration coefficient is detected, or a combination thereof, the calculation system 27 can reduce the baseline time based on the acquired device output variables. The baseline time reduction can be based on the conclusion that an increase in transmembrane pressure and a decrease in the ultrafiltration coefficient indicate buildup of the secondary membrane on the dialyzer semipermeable membrane, thus indicating a need to run the second operating mode more quickly or for a longer period, or both.

[0072] Figure 2A and Figure 2B A table of device setting variables is shown, comprising four columns: type of device setting variable, discrete correction amount, percentage correction amount, and correction factor. The type of device setting variable is a variable set by the device user or by the calculation system before or during patient treatment. The discrete correction amount, percentage correction amount, and correction factor are pre-programmed data points used by the calculation system to adjust the base time based on the input device setting variables before switching to the second operating mode. Specifically, the discrete correction amount is the amount of time, in minutes, that the calculation system subtracts from or adds to the base time. The percentage correction amount is the percentage of base time that the calculation system subtracts from or adds to the base time. The correction factor is a coefficient used by the calculation system to adjust the base time and thereby determine the time interval before each second operating mode (backwash). The correction factor is calculated based on the percentage correction amount; it is not used when the discrete correction amount is subtracted from or added to the base time. The correction factors and their equations are explained in more detail below.

[0073] Examples of device setting variables include replacement fluid rate, ultrafiltrate (UF) rate, and blood flow rate. The user or computing system can set the replacement fluid rate, UF rate, and blood flow rate. The computing system can then subtract or add time to a baseline time to determine when it can switch the extracorporeal blood device from a first operating mode to a second operating mode to backflush the semipermeable membrane. For example, if the blood flow rate is set to 200 ml / min, the percentage correction is -3%, thus reducing the time to calculate the baseline time by 3%. Similarly, if the UF rate is set to 2000 ml / h, the percentage correction is -10%, thus reducing the time to calculate the baseline time by 10%. Increased ultrafiltrate and blood flow rates result in a higher rate of secondary membrane buildup, therefore backflushing the semipermeable membrane earlier rather than later during treatment is preferable.

[0074] Included Figure 2A and 2BOther example types of device setting variables in the table include the type of dialyzer used in the extracorporeal blood therapy device (OPTIFLUX and dialyzer (custom)), hemodialysis filtration bolus volume, variation in ultrafiltration rate (Δ), variation in blood flow rate (Δ), and variation in replacement fluid rate (Δ). For these examples, discrete corrections and percentage corrections are provided. If the device setting type includes both discrete and percentage corrections, only one of the corrections is applied. For example, the larger of the two can be applied to the baseline time based on the remaining time before switching from a first operating mode to a second operating mode. For example, if an OPTIFLUX 250 NR dialyzer is used in the extracorporeal therapy device, the discrete correction is -4 minutes and the percentage correction is -10%. If the baseline time is 60 minutes, subtracting 10% is equivalent to subtracting 6 minutes (-6 minutes). The absolute value of the discrete correction of -4 minutes is less than that of -6 minutes, so the % correction of -10% will be applied to the baseline time to determine the time interval.

[0075] Figure 2B The table also shows corrections for pre-dilution and post-dilution used to introduce the replacement fluid into the bloodstream. Pre-dilution refers to pumping the replacement fluid into the blood line upstream of the dialyzer, while post-dilution refers to pumping the replacement fluid into the blood line downstream of the dialyzer. Figure 2B As shown in the table, for pre-dilution, the displacement fluid rate percentage correction is multiplied by -1, and for post-dilution, the displacement fluid rate correction is multiplied by 1. By multiplying the displacement fluid rate correction by -1, the negative percentage correction for the displacement fluid rate becomes a positive percentage correction, thereby increasing the baseline time rather than decreasing it. This is because the higher rate of pre-dilution blood flowing through the dialyzer reduces the rate of secondary membrane formation on the semipermeable membrane. Therefore, as... Figure 2A and Figure 2B As shown, if the displacement fluid flow rate is set to 100 ml / min, the percentage correction is -2%. Therefore, for post-dilution HF or HDF treatment, the time to calculate the baseline time is reduced by 2%, and for pre-dilution HF or HDF treatment, the time to calculate the baseline time is increased by +2% or 2%. Similarly, for pre-dilution HF or HDF treatment, increasing the displacement fluid flow rate by more than 100 ml / min will result in a baseline time correction of +4 minutes or +10%, instead of -4 minutes or -10% for post-dilution HF or HDF treatment.

[0076] Figure 3This is a table of device output variables, with four columns: type of device output variable, discrete correction amount, percentage correction amount, and correction factor. Device output variables are based on sensor readings from the extracorporeal blood therapy device sensed during the patient's treatment. Therefore, device output variables are distinguished from device setting variables, as device output variables are dynamically detected in real time by the computing system, while device setting variables are set by the user or the computing system before or at the start of treatment. The discrete correction amount is the amount of time, in minutes, subtracted from or added to the reference time, and the percentage correction amount is the percentage of time subtracted from or added to the reference time. The correction factor is a coefficient in the equation used to adjust the reference time and determine the time interval before each second operating mode (backflushing).

[0077] Figure 3 The table provides exemplary percentage deductions and corresponding correction factors for the range of detected venous pressure and detected transmembrane pressure. Figure 3 The table further provides exemplary minute and percentage deductions for changes in ultrafiltration coefficient (Δ), hematocrit (Hct) concentration (Δ), transmembrane pressure (Δ), and clearance (K) (Δ). The increment is a sensed variable compared to a sensed variable acquired at or near the start of treatment. If the device output variable type includes both discrete and percentage corrections, only one correction is applied. For example, providing the larger of two additions or subtractions will apply to the baseline time. If a discrete correction is applied, the correction factor is ignored.

[0078] use Figure 2A , Figure 2B and Figure 3 The table provides several examples of how to adjust the base time to obtain the time interval before backflushing, which can be achieved using the following equation:

[0079] Equation I: T i =T B •R n •Q s •Q uf •Q b •X d •P v •P tm

[0080] Among them, T i T is the time interval before backwashing. B It is the base time, R n It is the run count correction factor (cm), Q s Q is based on the displacement fluid rate and whether the displacement fluid is introduced into the blood before or after the dialyzer in cm. ufcm, Q is based on UF rate b It is based on blood flow rate in cm, X d cm, P based on dialyzer type v It is based on venous pressure in cm and P. tm It is cm based on transmembrane pressure.

[0081] Example 1: In this exemplary embodiment, the reference time (T) B The time is set to 60 minutes. Device settings variables for the extracorporeal blood therapy device can be configured to include the following: The replacement flow rate can be set to 200 ml / min. For a replacement rate of 200 ml / min, the percentage correction is -4%, therefore Q... s The correction factor is 0.96. An extracorporeal blood therapy device can be configured for hemodiafiltration therapy, wherein a replacement fluid is introduced into the blood line upstream of the dialyzer, i.e., pre-dilution. For pre-dilution, the percentage correction for the replacement flow rate is multiplied by -1, such that the percentage correction equals +4%. To determine the Q of pre-dilution therapy... s Q used in post-dilution treatment is equal to the value used in the treatment. s The intermediate variable Q of the value sn (Q) s (normal), then calculate the correction value Q. sm (Q) s (modified). To calculate Q sm The equation used is: Q sm =2-Q sn Therefore, for this particular example with a pre-dilution treatment modality, Q s =Q sm =2-0.96, which is 1.04. The ultrafiltration rate can be set to 1250 ml / hr. For an ultrafiltration rate of 1250 ml / min, the percentage correction is -6%, therefore the correction factor Q is... uf The value is 0.94. The blood flow rate can be set to 200 ml / min. The percentage correction for a blood flow rate of 200 ml / min is -3%, making Q... b The value is 0.97. When the OPTIFLUX 160NR dialyzer is used for extracorporeal blood therapy, the table shows that the percentage correction for the OPTIFLUX 160NR dialyzer is zero (0), therefore, X d The value is 1.

[0082] The device output variables of the extracorporeal blood therapy device can be detected during treatment as follows. The calculation system can detect when treatment has just begun and is therefore considered the first run. The percentage correction for the first run is -40%, therefore R... nEquals 0.6. The pressure sensor can detect a venous pressure of 250 mmHg. The percentage correction for the venous pressure sensed at 250 mmHg is -4%, therefore P v The value is 0.96. The pressure sensor can detect transmembrane pressure at 250 mmHg. The percentage correction for transmembrane pressure sensing at 250 mmHg is -6%, therefore P tm The value is 0.94, which is a correction of -6%.

[0083] In T B Equal to 60 minutes, R n equals 0.6, Q s Equal to 1.04, Q uf Equal to 0.94, Q b Equal to 0.97, X d Equal to 1, P v equals 0.96, P tm When the value is equal to 0.94, each input equation 1 in the correction coefficient, i.e., input equation T, will be corrected. i =T B •R n •Q s •Q uf •Q b •X d •P v •P tm To determine the time interval T of the first run i This is the time interval from the start of treatment until the first backflushing, i.e., the time spent operating in the first operating mode before switching to the second operating mode. Therefore, the equation for calculating the first time interval is 60 minutes multiplied by (•): 0.6•1.04•0.94•0.97•1.0•0.96•0.94 = 30.8. Therefore, the T for the first run... i It will equal approximately 30.8 minutes.

[0084] In this example, the first operating mode will initially run on the extracorporeal blood therapy device for approximately 30.8 minutes. Once the 30.8-minute time interval expires, the computing system switches the extracorporeal blood therapy device from the first operating mode to a second operating mode to run backflushing and remove secondary membrane buildup.

[0085] Example 2: After running the second operating mode for a certain period of time, for example, based on a second baseline time of five seconds, the system calculates an adjustable baseline time for switching the extracorporeal blood therapy device back to the first operating mode for 60 minutes. The baseline time is readjusted based on device setting variables and device output variables. For the second period of operation in the first operating mode, the machine setting variables are generally the same as in the example above, except that the correction factor is not reduced by 40% based on the first run, the number of runs, and the number of runs. For the second run, the number of runs correction factor is 1.0, meaning the baseline time based on the number of runs remains unchanged; the baseline time is not reduced by 40% because the second run will be a subsequent run, not the first. Therefore, the equation used to calculate the second iteration of the first operating mode is as follows: 60 minutes multiplied by (•) 1.04•0.94•0.97•1.0•0.96•0.94 = 51.34 minutes. Therefore, approximately 51.34 minutes after switching back from the second operating mode to the first operating mode, a backflushing is performed again. This second time interval can be based on one or more variables and / or changes and Figure 2A , Figure 2B and Figure 3 The corresponding correction factors shown in the table are used for adjustment.

[0086] Example 3: Under normal conditions, the 51.34 minutes calculated in Example 2 above would define the second time interval in the first operating mode. However, if, during the second time interval in the first operating mode, it is determined that the ultrafiltration coefficient has decreased by more than 15% after, for example, 30 minutes after the second entry into the first operating mode, and further, the transmembrane pressure has increased by more than 5% after 15 minutes after the second entry into the first operating mode, then two additional time interval reductions (corrections) will be made. Figure 3 As shown in the table, the output variables of these two devices will each indicate whether a four-minute discrete correction or a -10% correction should be applied.

[0087] Regarding the decrease in the ultrafiltration coefficient, if it is detected 30 minutes after the second entry into the first operating mode, then approximately 21.34 minutes would have remained before the second entry into the second operating mode. A -10% decrease corresponds to the correction factor value: ΔUFC cm=0.9. The discrete correction value and the % value to be applied are compared using the following equation: % time value to be applied = (remaining time) * (1 - correction factor). For ΔUFC, the % time value to be applied is: (21.34 minutes) * (1 - 0.9) = 2.134 minutes. Then, since 4 minutes is greater than 2.134 minutes, the discrete correction is used for the detected decrease in the ultrafiltration coefficient. Using the same comparison method, for the increase in transmembrane pressure 15 minutes after the second entry into the first operating mode, the % time value to be applied is calculated as: (51.34 minutes - 15 minutes) * (1 - 0.9) = 3.634 minutes. Again, the discrete correction of 4 minutes is larger and is therefore used, and as a result, a total of 8 minutes will be subtracted from the 51.34-minute interval. When using Figure 3 As shown in the table, the eight minutes will be generated by a four-minute reduction based on ΔUFC and a four-minute reduction based on ΔTMP, for a total reduction of eight minutes. Therefore, the control system will cause the system to perform backflushing after the corrected time interval of 43.34 minutes instead of 51.34 minutes. In this case, the second iteration of the first operating mode will last 43.34 minutes. Therefore, in cases where the clearance coefficient, transmembrane pressure, their combination, or similar factors change significantly during treatment, Equation II is then used to calculate the second time interval, and is shown here when only discrete corrections are applied:

[0088] Equation II: T i = (T B •R n •Q s •Q uf •Q b •X d •P v •P tm )+Mod X

[0089] Among them, T i T is the time interval before backwashing. B It is the base time, R n It is the run count correction factor (cm), Q s Q is based on the displacement fluid rate and whether the displacement fluid is introduced into the blood before or after the dialyzer in cm. uf cm, Q is based on UF rate b It is based on blood flow rate in cm, X d cm, P based on dialyzer type v It is based on venous pressure in cm and P. tm cm, Mod based on transmembrane pressure X It is the sum of the discrete corrections to be considered. In Example 3 above, Mod...X It is the sum of the discrete correction ΔTMP (5%) and the discrete correction ΔUFC > 15% (reduction). From Figure 3 It can be seen that ΔTMP (5%) equals -4 minutes, and ΔUFC > 15% (reduction) equals -4 minutes. Therefore, Mod X It is -8 minutes. Therefore, the processor operates from a time limit relative to the time limit based solely on the correction factor T. B R n Q s Q uf Q b X d P v and P tm T in terms of calculation time i Subtract eight minutes from the middle. Therefore, considering Mod X Time interval T i It's 43.43 minutes, not 51.43 minutes. Mod X It can be any applicable value.

[0090] like Figure 2A , Figure 2B and Figure 3 The other correction factors shown can also be considered by applying Equation III shown here:

[0091] Equation III: T i+1 = (T B •R n •Q s •Q uf •Q b •X d •P v •P tm )+(-(T i -T Ei • (1-X) A ))+Mod X

[0092] Among them, T i+1 T is the newly calculated time interval before backwashing. i T is the initially calculated time interval before backwashing. B It is the base time, R n It is the run count correction factor (cm), Q s Q is based on the displacement fluid rate and whether the displacement fluid is introduced into the blood before or after the dialyzer in cm. uf cm, Q is based on UF rate b It is based on blood flow rate in cm, X d cm, P based on dialyzer type vIt is based on venous pressure in cm and P. tm It is based on transmembrane pressure in cm and T. Ei This is the time elapsed since the start of the current first operating mode, Mod. X It is the sum of the discrete corrections to be considered, and X A This is an additional applicable correction factor. In T i+1 T i and T Ei The 'i' in the equation indicates the iterative property of equation III.

[0093] Example 4: In one example, X detected a clearance rate decrease of more than 15% 10 minutes after entering the second first operating mode. A =ΔK cm =0.9. For simplicity, we will assume R = 0.9. n Q s Q uf Q b X d P tm and P v Equals 1, therefore T i =T b =60 minutes. As described in Example 3 above, the comparison is used to determine (-((T)). i -T Ei • (1-X) A The larger absolute value of the variable is referred to in this paper as the "% value to be applied" and the discrete correction for the relevant device output or device setting variable. For device output variables with a clearance rate decrease greater than 15%, the discrete correction is -4 minutes. The % value to be applied is calculated as follows: (-(60 minutes - 10 minutes) * (1 - 0.9) = -5 minutes. Negative five (-5) minutes has a larger absolute value than -4 minutes, therefore, the % value to be applied is used instead of the discrete correction. Therefore, Equation III yields: 60 minutes + (-5 minutes) = 55 minutes = T i +1 .

[0094] To illustrate the iterative nature of Equation III, and in another exemplary case, in addition to detecting a clearance rate decrease greater than 15% at 10 minutes after entering the second first operating mode, a hematocrit (Hct) increase of 15% is detected at 13 minutes after entering the second first operating mode. The percentage value to be applied for the detected hematocrit increase is calculated as follows: (-(55 minutes - 13 minutes) * (1 - 0.9)) = -4.2 minutes, and the discrete correction for the device output variable increase of Hct > 15% is -4 minutes. Since -4.2 (-4.2) minutes has a larger absolute value than -4 minutes, the percentage value to be applied is used instead of the discrete correction. Therefore, Equation III yields: 55 minutes + (-4.2 minutes) = 50.8 minutes = T i+1 Therefore, the newly calculated time interval T, which was initially calculated to be 60 minutes, is... i+1 This will reduce the number of backwashes to two, resulting in a final value of only 50.8 minutes. Therefore, the second backwash will occur more than 9 minutes earlier than if no % value was introduced for application.

[0095] Equation IV shown below can be used to explain the parameters, such as Q. s or P tm This includes situations where the value of the applied % correction amount changes.

[0096] Equation IV: T i+1 = (T B •R n •Q s •Q uf •Q b •X d •P v •P tm )+((T) i –T Ei )•((2-Y Aold )*Y Anew ))-(T i –T Ei ))+(-((T i –T Ei ))•((1-X A ))+Mod X

[0097] Among them, T i+1 T is the newly calculated time interval before backwashing. i T is the initially calculated time interval before backwashing. B It is the base time, R n It is the run count correction factor (cm), Q s Q is based on the displacement fluid rate and whether the displacement fluid is introduced into the blood before or after the dialyzer in cm.uf cm, Q is based on UF rate b It is based on blood flow rate in cm, X d cm, P based on dialyzer type v It is based on venous pressure in cm and P. tm It is based on transmembrane pressure in cm and T. Ei This is the time elapsed since the start of the current first operating mode, Mod. X X is the sum of the discrete corrections to be considered. A It is an additional applicable correction factor, Y Aold It is for the observed changed Q s Q uf Q b X d P tm or P v The previously applied correction factor, Y Anew It is for the observed changed Q s Q uf Q b X d P tm or P v The new applicable correction factor. In T i+1 T i and T Ei The 'i' in the equation indicates the iterative property of equation IV.

[0098] Example 5: If, after 5 minutes in the second operating mode, a blood flow rate is detected to increase from 125 ml / min to 175 ml / min, as in Example 4, for simplicity, we will assume R... n Q s Q uf X d P tm and P v Q equals 1. For a blood flow rate of 125 ml / min, Q b It also equals 1, therefore T i =T b =60 minutes. The percentage correction contributed by the blood flow rate device setting variable will change from 0% to -3%, therefore, Y Aold =Q b =1, Y Anew =0.97. ((T) i -T Ei )•((2-Y Aold )*Y Anew ))-(T i -T EiThe value of ), referred to in this paper as the % value of the correction to be applied, is calculated as follows: ((60 minutes - 5 minutes) • ((2 - 1) * 0.97) - (60 minutes - 5 minutes)) = -1.65 minutes. Therefore, Equation IV yields: 60 minutes + (-1.65 minutes) = 58.35 minutes = T i +1 .

[0099] To illustrate the iterative nature of Equation IV, and considering that, in addition to detecting an increase in blood flow rate from 125 ml / min to 175 ml / min after 5 minutes of entering the second first operating mode, the blood flow rate decreases back to 125 ml / min after 10 minutes of entering the second first operating mode. As a result of this second change in blood flow rate, the percentage correction contributed by the blood flow rate device setting variable will change from -3% to 0%, therefore Y Aold =0.97, Y Anew =1. The percentage value of the correction to be applied is calculated as follows:

[0100] ((58.35 minutes - 10 minutes) • ((2 - 0.97) * 1) - (58.35 minutes - 10 minutes)) = +1.45 minutes. Therefore, equation IV yields: 58.35 minutes + (1.45 minutes) = 59.8 minutes = T i+1 Equation IV solves the problem of Q ensuring the change in the value of the applied % correction. b Q s Q uf X d P tm and P v Any changes.

[0101] Figure 2A , Figure 2B and Figure 3 The examples of correction factors are not limited to those that can be considered or used in a particular apparatus or method, but rather represent a multitude of correction factors that can be applied. The values ​​of discrete and percentage corrections are not limiting.

[0102] Considering the adjustments to dialysate flow rate, replacement fluid flow rate, and blood flow rate, and their effects on transmembrane pressure, the initial TMP value can be corrected for use when an increase in TMP is detected. For example, if a 2% increase in TMP is detected, then changing the blood flow rate, dialysate flow rate, or replacement fluid flow rate will result in a correlated change in TMP. A new, stable TMP value (in Q) will be observed. s Q d Or Q bAfter 5 minutes of no change). Based on the previously detected 2% increase in TMP, a corrected baseline TMP value will be generated such that: Corrected baseline TMP * (1.02) = (Stable baseline TMP). This corrected baseline TMP value will then be used as the basis for detecting ΔTMP, which truly guarantees the correction of the time interval prior to backflushing. In doing so, the detection of the TMP increase will not be erroneously triggered by adjustments to the dialysate flow rate, replacement fluid flow rate, or blood flow rate; the detection of the TMP increase will be based on… Figure 3 The bottom row shows the basis for adjusting the calculated time interval prior to backflushing. Unless a 5%, 10%, or 15% increase in the corrected baseline TMP is detected, the time interval prior to backflushing will not change; this change will be addressed by applying a discrete correction amount or a % value to be applied via Equation III. Any additional changes to the calculated time interval required before backflushing due to changes in the values ​​of the device setting variable dialysate flow rate, displacement fluid flow rate, blood flow rate, or the device output variable transmembrane pressure will be addressed as needed by applying a % value of the correction to be applied via Equation IV.

[0103] Figure 4A and Figure 4B These are the left and right portions of a schematic diagram of the dialysate circuit 400 of another embodiment of the extracorporeal blood therapy device. Figure 4A The pipeline terminals A, B, C, and D shown continue to extend and respectively connect with... Figure 4B The pipeline terminals A, B, C, and D shown are in fluid communication. The extracorporeal blood therapy device includes a dialyzer 401, which comprises a blood chamber 402 and a dialysate chamber 403 separated by a semipermeable membrane 404. The dialysate circuit 400 includes a water source 413 for preparing fresh dialysate. The water source 413 is connected via a first portion 416A of a supply line 416, in which water is mixed with bicarbonate supplied by a bicarbonate pump 450 and with electrolytes supplied by a concentrate pump 460 to form dialysate. The dialysate then travels through a second portion 416B of the supply line 416, moving from the second portion 416B to the fresh dialysate side 406A of the first balancing chamber 406 and to the fresh dialysate side 408A of the second balancing chamber 408. Fresh dialysate exiting the fresh dialysate sides 406A and 408A then enters the dialysate inlet 440 of the dialysate chamber 403 through the third section 416C of the supply line 416. The fresh dialysate can be used as a flushing liquid or a preparation liquid. The pressure of the dialysate in the supply line 416, just before entering the dialysate chamber 403, can be sensed by a pressure transducer 433 arranged along the third section 416C of the supply line 416.

[0104] The dialysate outlet 444 of the dialysate chamber 403 is connected to the dialysate removal line 418. Used dialysate, ultrafiltrate, combinations thereof, or fresh dialysate during perfusion leave the dialysate outlet 444 and move through the dialysate removal line 418. The pressure in the dialysate removal line 418 can be sensed by a pressure transducer 432 arranged along the dialysate removal line 418.

[0105] Dialysate removed from dialysate chamber 403 can be moved to discharge system 480 or into used dialysate sides 406B and 408B of balancing chambers 406 and 408, respectively, by the action of ultrafiltrate pump 423 and flow pump 417. Pressure sensor 419 is located downstream of flow pump 417 and configured to sense pressure in the line downstream of pump 417. Ultrafiltrate pump 423 may be part of ultrafiltration system 422. During perfusion, dialysate removed along dialysate removal line 418 can be moved at least partially along dialysate recirculation line 415 by degassing pump 425. Dialysate outlet valve 420 is located downstream of dialysate chamber 403 and outlet 444 along dialysate removal line 418. Dialysate outlet valve 420 remains open during the first operating mode described herein and remains closed for a period of time during the second operating mode described herein.

[0106] Figure 5A and Figure 5B It shows the use of Figure 1 or Figure 3 A and Figure 3 A flowchart of a method for treating a patient using an extracorporeal blood therapy device (ECH) B. The ECH treatment device begins treatment in a first operating mode. Then, the computational system activates a secondary membrane-mediated algorithm in step 300, which constitutes entry into a second operating mode. In step 320, if the treatment is hemodialysis filtration or hemofiltration, the replacement pump is stopped. Otherwise, if it is hemodialysis treatment, this step is skipped. In step 330, the ultrafiltrate pump is stopped. In step 340, the transmembrane and venous pressure limits may be widened. During typical treatment using the ECH device, transmembrane and venous pressures are monitored to detect malfunctions. With the dialysate outlet valve expected to remain closed for a period of time, the TMP limit is temporarily widened to the machine's hard limit to prevent the detection of false malfunctions. As shown in step 345, steps involving adjusting the dialysate and blood flow rates may be provided, if applicable. As a result of stopping the ultrafiltrate pump in step 330 and optionally adjusting the dialysate and blood flow rates in step 345, the venous pressure limit is temporarily widened to the machine's hard limit in step 340 to prevent the detection of false malfunctions.

[0107] When the balancing chamber is part of the device, in step 350, monitoring is performed to initiate a new balancing chamber cycle. The balancing chamber cycles between two states, wherein in a first state, the fresh side of the balancing chamber is filled, thereby emptying the used side of the balancing chamber, and in a second state, the used side of the balancing chamber is filled, thereby emptying the fresh side of the balancing chamber.

[0108] If a balance chamber exists but balance chamber circulation is not initiated, the process can be prevented from proceeding to the next step until balance chamber circulation is initiated. If a balance chamber does not exist, step 350 is skipped. Then, in step 360, capacity introduction is initiated by closing the dialysate outlet valve and disabling checks for flow error and required pressure holding test (PHT).

[0109] If a balance chamber is present, the dialysate outlet valve is closed during the first part of the balance chamber cycle, and then reopened to allow the balance chamber cycle to complete. Alternatively, if no balance chamber is present, the dialysate outlet valve is closed during the duration of step 360. Then, in step 370, a check is performed to determine if the balance cycle is complete. The process should not proceed to the next step unless the balance cycle is complete and ready to move from the first state to the second state or from the second state to the first state. One exception is an unforeseen event in the second operating mode where the dialysate outlet valve is stuck closed, in which case the dialyzer will be immediately isolated by closing the dialysate inlet valve to ensure patient safety. Once the balance cycle is complete, in step 380, the process is initiated by restoring the ultrafiltration rate, restoring the dialysate flow rate, blood flow rate, and replacement fluid flow rate (if applicable), and performing a flow error / PHT check after two balance chamber cycles. The completion of step 380 constitutes the completion of the second operating mode and re-entry into the first operating mode.

[0110] Upon re-entering the first operating mode, transmembrane pressure and venous pressure limits are restored, and the fluid volume introduced into the patient by backflushing is restored by increasing ultrafiltration for approximately 5 to 10 minutes in step 390. Then, in step 400, if ultrafiltration calculation is available, the ultrafiltration coefficient is recalculated by triggering the ultrafiltration coefficient / PHT.

[0111] It should be assumed that when the system is in an alarm-free state, the transition from the first operating mode to the second operating mode occurs only if the dialysate conductivity, dialysate temperature, arterial pressure, venous pressure, and transmembrane pressure are within their respective acceptable ranges prior to the transition. When the values ​​of arterial pressure, venous pressure, and / or transmembrane pressure are close to their respective alarm upper or lower limits, the blood flow rate, dialysate flow rate, or a combination thereof may be adjusted during the second operating mode to minimize changes in arterial pressure, venous pressure, and / or transmembrane pressure.

[0112] It should be further assumed that if the second operating mode is entered while the machine is perfusing and not connected to a patient, the baseline volume of blood to be delivered to the dialyzer chambers during the second operating mode can be delivered within the upper limit of the duration described herein. The time interval prior to backflushing during perfusing will not be based on Equations I-IV, and entry into the secondary operating mode during perfusing can occur at the start of perfusing, at the end of perfusing, at some point during perfusing, or during a combination of these.

[0113] This invention may include any combination of the various features or embodiments described above and / or below as set forth in sentences and / or paragraphs. Any combination of the features disclosed herein is considered part of this invention, and there is no limitation on the composable features.

[0114] The applicant specifically incorporates the entire contents of all cited references into this disclosure. Furthermore, when quantities, concentrations, or other values ​​or parameters are given as a list of ranges, preferred ranges, or preferred upper and lower limits, this should be understood as specifically disclosing all ranges formed by any pair of any upper or preferred value and any lower or preferred value, regardless of whether the range is disclosed individually. Where numerical ranges are listed herein, unless otherwise stated, the range is intended to include its endpoints and all integers and fractions within that range. This does not mean that the scope of the invention is limited to the specific values ​​listed when the range is defined.

[0115] Other embodiments of the invention will be apparent to those skilled in the art in light of this specification and the practice of the invention disclosed herein. This specification and the embodiments are intended to be considered exemplary only, and the true scope and spirit of the invention are indicated by the appended claims and their equivalents.

Claims

1. An extracorporeal blood therapy device, comprising: A dialyzer includes a blood chamber, a dialysate chamber, a dialysate inlet, a dialysate outlet, and a semipermeable membrane, wherein the blood chamber and the dialysate chamber are separated from each other by the semipermeable membrane; A dialyzer supply line leads to the dialysate inlet and is configured to supply dialysate to the dialysate chamber; A dialyzer discharge line is provided, which is led out from the dialysate outlet and configured to drain the dialysate from the dialysate chamber. A dialysate pump configured to pump dialysate through the dialyzer supply line to the dialysate chamber and through the dialyzer discharge line from the dialysate chamber. Dialysis fluid outlet valve; A blood pump configured to pump blood through the dialyzer into the blood chamber; as well as A processor and a sensor that communicates with the processor and is configured to generate sensor data. A balancing device includes a balancing chamber, a balancing supply line leading to the balancing chamber and configured to supply dialysate from a dialysate source into the balancing chamber, and a balancing discharge line extending from the balancing chamber and configured to drain dialysate from the balancing chamber into a discharge system, wherein... The dialyzer supply line extends from the balance chamber and is configured to supply dialysate from the balance chamber to the dialysate chamber, and the dialyzer discharge line leads to the balance chamber and is configured to supply dialysate from the dialysate chamber to the balance chamber. The dialysate pump or the blood pump, or both, are configured to operate in a first operating mode and a second operating mode of the extracorporeal blood therapy device. The first operating mode operates in a configuration in which the dialysate outlet valve is opened, allowing dialysate to flow through the dialyzer supply line, through the dialysate chamber, into and through the dialyzer discharge line, and... The second operating mode operates in a configuration in which the dialysate outlet valve remains closed for a period of time to prevent dialysate from flowing through the dialyzer discharge line, and allows a certain volume of dialysate to pass from the dialysate chamber through the semipermeable membrane into the blood chamber. The processor is configured to process the sensor data and, based on the processed sensor data, switch the extracorporeal blood therapy device from the first operating mode to the second operating mode for a period of time. The processor is configured to run an initial first operating mode phase and continue for a main operating period, the initial first operating mode phase starting at the beginning of treatment, wherein the processor is configured to switch the extracorporeal blood therapy device from the first operating mode to the second operating mode once the operating period expires. The processor is programmed to switch from the first operating mode to the second operating mode when the time interval calculated according to Equation I expires: Equation I: T i =T B •R n •Q s •Q uf •Q b •X d •P v •P tm Among them, T i It is the time interval before backwashing; T B It is the base time; R n It is the correction factor for the number of runs (cm); Q s Q is a correction factor (cm) based on the displacement fluid rate and whether the displacement fluid is introduced into the blood before or after the dialyzer; uf It is a correction factor (cm) based on the UF rate; Q b It is a correction factor (cm) based on blood flow rate; X d The correction factor (cm) is based on dialyzer type; P v This is a correction factor (cm) based on venous pressure; P tm It is a correction factor (cm) based on transmembrane pressure. The second operating mode is a continuous operation period of no more than 30 seconds.

2. The extracorporeal blood therapy device according to claim 1, wherein, The dialysate pump and blood pump are configured to operate at a first operating speed and a second operating speed, and the dialysate pump and blood pump are configured to operate at their respective first operating speed during the first operating mode and at their respective second operating speed during the second operating mode.

3. The extracorporeal blood therapy device according to claim 1, wherein, The extracorporeal blood therapy device further includes an ultrafiltrate pump configured to switch between an operating state and a non-operating state. In the operating state, the ultrafiltrate pump draws liquid from the blood chamber through the semipermeable membrane into the dialysate chamber and then removes it from the dialysate chamber. In the second operating mode, the ultrafiltrate pump is switched to the non-operating state.

4. The extracorporeal blood therapy device according to claim 3, wherein, The extracorporeal blood therapy device also includes an ultrafiltration line branching off from the dialyzer discharge line downstream of the dialysate outlet valve, wherein the ultrafiltration pump is disposed on the ultrafiltration line.

5. The extracorporeal blood therapy device according to claim 3, wherein, The ultrafiltration pump is configured to operate at a faster rate during at least one time period in the first operating mode to remove a volume of liquid from the blood chamber equivalent to the volume of dialysate introduced during the second operating mode.

6. The extracorporeal blood therapy device according to claim 1, wherein, The processor is configured to run an initial first operating mode phase and continue for a main operating period, the initial first operating mode phase starting at the start of perfusion, wherein the processor is configured to switch the extracorporeal blood therapy device from the first operating mode to the second operating mode once the operating period expires.

7. The extracorporeal blood therapy device according to claim 6, wherein, The processor is configured to enable the extracorporeal blood therapy device to alternate between a first operating mode and a second operating mode at a certain frequency in a series of multiple operating modes during the perfusion process, wherein each of the multiple operating modes includes a corresponding operating time period.

8. The extracorporeal blood therapy device according to claim 1, wherein, The processor is configured to modify the main operating time period based on at least one device set variable or at least one device output variable or both, wherein the at least one device output variable is determined by the sensor data.

9. The extracorporeal blood therapy device according to claim 1, wherein, The extracorporeal blood therapy device further includes a processor and a sensor communicating with the processor and configured to generate sensor data, wherein the processor is configured to process the sensor data and switch the extracorporeal blood therapy device from a first operating mode to a second operating mode based on the processed sensor data for a period of time, the processor is configured to switch the extracorporeal blood therapy device from the second operating mode to the first operating mode once the main operating period expires, and the processor is configured to modify the main operating period based on at least one device set variable or at least one device output variable or both, wherein the at least one device output variable is determined by the sensor data.

10. The extracorporeal blood therapy device according to claim 9, wherein, The at least one device setting variable includes at least one of the following: treatment type, displacement fluid flow rate, ultrafiltrate flow rate, blood flow rate, dialyzer type, displacement fluid injection volume, or a combination thereof.

11. The extracorporeal blood therapy device according to claim 9, wherein, The at least one device output variable includes at least one of urea clearance rate, ultrafiltration coefficient, venous pressure, transmembrane pressure, number of runs, hematocrit value, or a combination thereof.

12. The extracorporeal blood therapy device according to claim 1, wherein, The processor is configured to enable the extracorporeal blood therapy device to alternate between a first operating mode and a second operating mode at a certain frequency in a series of multiple operating modes during the treatment process, wherein each of the multiple operating modes includes a corresponding operating time period.

13. The extracorporeal blood therapy device according to claim 12, wherein, The processor is configured to modify at least one of the frequency and the corresponding operating time period based on at least one device set variable or at least one device output variable or both, wherein the at least one device output variable is determined by the sensor data.

14. The extracorporeal blood therapy device according to claim 13, wherein, The at least one device setting variable includes at least one of the following: treatment type, displacement fluid flow rate, ultrafiltration flow rate, blood flow rate, dialyzer type, displacement fluid injection volume, or a combination thereof.

15. The extracorporeal blood therapy device according to claim 13, wherein, The at least one device output variable includes at least one of urea clearance rate, ultrafiltration coefficient, venous pressure, transmembrane pressure, number of runs, hematocrit value, or a combination thereof.

16. The extracorporeal blood therapy device according to claim 1, wherein, The processor is configured to: (1) process sensor data to determine the ultrafiltration coefficient within a time interval during treatment; and (2) compare the change in the ultrafiltration coefficient with a threshold. (3) When the threshold is exceeded, accelerate the switching of the extracorporeal blood therapy device from the first operating mode to the second operating mode.

17. The extracorporeal blood therapy device according to claim 16, wherein, The sensor includes at least a first pressure sensor configured to detect the pressure of blood flowing out of the blood chamber and a second pressure sensor configured to detect the pressure of dialysate flowing out of the dialysate chamber.

18. The extracorporeal blood therapy device according to claim 1, wherein, The extracorporeal blood therapy device further includes an extracorporeal blood circuit in fluid communication with the blood chamber. The blood chamber also includes a blood chamber inlet and a blood chamber outlet. The extracorporeal blood circuit includes a blood pump, a blood supply line leading to the blood chamber inlet, and a blood removal line leading out from the blood chamber outlet. The blood pump is configured to pump blood through the blood supply line and the blood chamber inlet into the blood chamber and pump it out from the blood chamber outlet and the blood removal line.

19. The extracorporeal blood therapy device according to claim 18, wherein, The blood pump is configured to reduce its speed during the second operating mode compared to the first operating mode.

20. The extracorporeal blood therapy device according to claim 18, wherein, The blood pump is configured to stop during the second operating mode.

21. The extracorporeal blood therapy device according to claim 18, wherein, The extracorporeal blood therapy device further includes a replacement line and a replacement pump disposed on the replacement line, wherein the replacement line branches off from the dialyzer supply line and connects to the blood removal line, the replacement pump is configured to pump fluid from the dialyzer supply line to the blood removal line through the replacement line during a first operating mode, and the replacement pump is configured to stop during a second operating mode.

22. The extracorporeal blood therapy device according to claim 1, wherein, The extracorporeal blood therapy device further includes an extracorporeal blood circuit in fluid communication with the blood chamber, the extracorporeal blood circuit including a blood pump, wherein the blood pump is controlled by the processor and the processor is configured to reduce the pump speed during the second operating mode compared to the first operating mode.

23. The extracorporeal blood therapy device according to claim 1, wherein, The extracorporeal blood therapy device also includes an air separation chamber disposed between the at least one dialysate pump and the dialysate outlet valve.

24. The extracorporeal blood therapy device according to claim 1, wherein, The volume of the dialysis fluid is 3 ml to 20 ml.

25. The extracorporeal blood therapy device according to claim 1, wherein, The volume of the dialysis fluid is 3 ml to 6 ml.

Citation Information

Patent Citations

  • A system and a method for renal replacement therapy

    US20200155745A1